Jean-François Formela is a partner and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics.
He is chairman of IFM Therapeutics and serves on the boards of Intellia Therapeutics (NASDAQ: NTLA), F-star, Kyn Therapeutics, Spero Therapeutics (NASDAQ: SPRO), and Translate Bio which he co-founded.
Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), Arteaus Therapeutics (acquired by Eli Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM, acquired by Fresenius Medical) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Eli Lilly). He was also an investor in CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP).
Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough where he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. He began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.
Jean-François is a member of the MGH Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. He received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.